Trial Profile
The effects of anaglipitin, a DPP-4 inhibitor, on blood lipids in type 2 diabetic patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2020
Price :
$35
*
At a glance
- Drugs Anagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ANGELS
- 06 Apr 2020 Status changed from active, no longer recruiting to completed.
- 26 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Jul 2014 New trial record